Abstract PD8-01: CDH1 mutated classic and pleomorphic invasive lobular breast carcinomas differ in genomic signatures and opportunities for targeted and immunotherapies
JS Ross , J Chung , JE Elvin , J-A Vergilio
Cancer Research 78
2018
Abstract P2-09-15: NTRK fusions in breast cancer: Clinical, pathologic and genomic findings
JS Ross , J Chung , JE Elvin , J-A Vergilio
Cancer Research 78
26
2018
Abstract P2-12-01: Comprehensive genomic profiling of 34 cases of breast angiosarcoma
V Ravi , R Madison , AB Schrock , G Cote
Cancer Research 77
2017
Abstract P3-07-02: Are we missing actionable targets in breast cancer? Novel insights into recurrent Ret alterations
KM Hirshfield , BS Paratala , A Hindoyan , SC Dolfi
Cancer Research 77
2017
Abstract P3-07-05: Non-amplification ERBB2 genomic alterations in 5,605 cases of refractory and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies
JS Ross , K Wang , SM Ali , S Chumsri
Cancer Research 76
1
2016
Abstract P6-03-12: Comprehensive genomic profiling of clinically advanced mucinous carcinoma of the breast
K Wang , SM Ali , D Khaira , JA Elvin
Cancer Research 76
1
2016
Abstract P6-03-02: EGFR genomic alterations in 5,605 cases of refractory and metastatic breast cancer
R Yelensky , D Lipson , J Chmielecki , VA Miller
Cancer Research 76
1
2016
Abstract PD6-08: IMAGE: Individualized molecular analyses guide efforts in breast cancer with comprehensive genomic profiling of tissue and plasma tumor DNA
HA Parsons , JA Beaver , A Cimino-Mathews , J Zorzi
Cancer Research 76
2016
HER2 protein expression predicts response to trastuzumab in FISH-positive patients.
A Lipton , SM Ali , K Leitzel , W Koestler
Cancer Research 69 32
9
2009
Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov. 2015; 5: 850–859. doi: 10.1158/2159-8290
GM Frampton , SM Ali , M Rosenzweig , J Chmielecki
Go to original source... Go to PubMed
115
2015
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017; 9 (1): 34
ZR Chalmers , CF Connelly , D Fabrizio , L Gay
54
Immune checkpoint inhibitor (ICPI) efficacy and resistance detected by comprehensive genomic profiling (CGP) in non-small cell lung cancer (NSCLC)
JS Ross , ME Goldberg , LA Albacker , LM Gay
Annals of Oncology 28 v404 -v404
11
2017
Topography of tumor mutational burden (TMB) and immune-related genomic alterations (GA) across gastrointestinal malignancies (GIm): a study of 22,570 cases
SJ Klempner , GM Frampton , J Chao , M Bailey
Annals of Oncology 28 v415 -v415
2
2017
Comprehensive genomic profiling (CGP) and tumor mutational burden (TMB) assessment in subtypes of metastatic melanoma
JS Ross , JA Carlson , JA Elvin , J-A Vergilio
Annals of Oncology 28 v430 -v431
2017
Comprehensive genomic profiling of primary and metastatic CDH1 mutated classic and pleomorphic invasive lobular breast carcinomas reveals markers of hormonal therapy resistance and opportunities for targeted therapies
JS Ross , LM Gay , JA Elvin , J Suh
Annals of Oncology 28 v75 -v76
2017
84 Thursday 20 November 2014 Poster Session–DNA Repair Modulation (including PARP, CHK, ATR, ATM)
J Chmielecki , KE Hutchinson , GM Frampton , ZR Chalmers
Genomic profiling of 114,200 advanced cancers identifies recurrent kinase domain duplications (KDD) and oncogenic rearrangements (RE) across diverse tumor types
LM Gay , D Pavlick , J Chung , S Ramkissoon
Annals of Oncology 28 v595 -v595
6
2017
Re: Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-Invasive Bladder Carcinoma with Variant Histologies
A Necchi , M Bandini , G Calareso , D Raggi
JOURNAL OF UROLOGY 207 ( 4) 926 -926
2022
Re: MultiparametricMagnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study
A Necchi , M Bandini , G Calareso , D Raggi
THE JOURNAL OF UROLOGY 207 ( 4) 927 -928
2022
Comprehensive genomic profiling (CGP) of chemotherapy-resistant, primary mediastinal nonseminomatous germ cell tumors (PMNSGCT)
A Necchi , G Bratslavsky , RJ Corona , J Chung
Annals of Oncology 29
2018
Alexa Schrock Garrett M Frampton Doron Lipson Sai-Hong Ignatius Ou Samuel Klempner, MD Zachary R Chalmers James X. Sun Roman Yelensky Sumanta Pal David M. Sabatini Shridar Ganesan Sugganth Daniel Dos Sarbassov Lee Albacker maurizio colecchia Do-Hyung Kim Alberto Briganti Christine M. Lovly, MD, PhD Andrea Gallina